Effect of BioDMARDs on Diabetes risk in 6400+ Psoriasis pts IL-23i and IL-17Ai associated w/ -lower risks of diabetes -Diabetic nephropathy -Stage 3–5 CKD and reduced risk compared to TNFi treated and bionaive pts Adjustment on several variables, but not disease severity https://t.co/TDIHXJOC2T

• https://x.com/AurelieRheumo/status/1982514480211693706/photo/1
• https://x.com/AurelieRheumo/status/1982514480211693706/photo/1

Leflunomide - a perennial question in GCA, that we still haven’t answered (as this meta-analysis shows), despite clear potential. We are getting a clearer idea of the strengths/limitations of MTX in GCA, is it now time to get better clarity for LEF? #ACR25 ABST0731 @RheumNow https://t.co/ycuvPx8Xdg

• https://x.com/drdavidliew/status/1982502466483855856/photo/1

Avacopan in the real world: we need to be braver If we want to get steroid-sparing benefit in AAV, we need to trust it claims data shows modest PNL reduction with avacopan some manifestations are harder to taper in, but others we just need to be bolder #ACR25 ABST0726 @RheumNow https://t.co/51nGdpR2db

• https://x.com/drdavidliew/status/1982488060941213929/photo/1

A systematic review by Dr. SRamiro et al evaluated efficacy of b/tsDMARDs on peripheral axSpA Majority on bDMARDs (TNFi, n=24; IL-17, n=13) Most of the SMDs were small --> b/tsDMARDs showed small to moderate effects on peripheral arthritis & enthesitis. #ACR25 @RheumNow Abs0588 https://t.co/yGXcqhZ1Uv

• https://x.com/RHEUMarampa/status/1982490153852833879/photo/1

ASAS recommends standardised reporting for 20 key outcomes in axSpA trials, 10 for all studies, 10 specific to DMARD trials. Formats include mean (±SD), mean change, and categorical thresholds for ASDAS, ASAS-HI, and extra-musculoskeletal manifestations. 85% of ASAS members https://t.co/VQwPaTRIOl

• https://x.com/synovialjoints/status/1982484870388498728/photo/1

#ACR25 Abstr#776 2-Year SELECT-GCA RCT showed that #GCA patients receiving continuous UPA15 to 2-yr maintained their remission (69%) vs those who switched to PBO after in remission for ≥24 weeks (29%). Lower serious infection but higher herpes zoster in UPA15. One VTE @RheumNow https://t.co/FCTNqCVxiZ

• https://x.com/Yuz6Yusof/status/1982486937022939200/photo/1
• https://x.com/Yuz6Yusof/status/1982486937022939200/photo/1

Heydari-Kamjani et al. Risk of DILI with avacopan. Real world study, propensity score matching. Risk DILI 2% with avacopan vs 1.9% PBO @RheumNow #ACR25 Abstr#724 https://t.co/UhVkcXEYjF

• https://x.com/RichardPAConway/status/1982482352962998313/photo/1

2-Year data from SELECT-GCA Phase 3 UPA in GCA Re-randomization & 52 weeks extension UPA 15mg vs. PBO -Risk of flare 90% lower -Complete remission 70% vs 20% -Cumulative GC 1g difference -No new safety signal The quick relapse after stopping UPA indicates we are really looking https://t.co/c1khywnPNv

• https://x.com/AurelieRheumo/status/1982478272697909405/photo/1
• https://x.com/AurelieRheumo/status/1982478272697909405/photo/1

Immune-Mediated Necrotizing Myopathy @EleniTiniakou #ACR25 *Younger pts tend to have a more aggressive disease *IVIG and RTX can be considered first-line rx for anti-HMGCR and anti-SRP+, respectively *CYC and plasmapheresis may be options in cases of aggressive disease https://t.co/zWDX79gqlf

• https://x.com/RheumQuarterly/status/1982461272500097265/photo/1

Real world effectiveness of voclosporin for SLE Reduction in UPCR from 2.1 at b/l to 0.9 at 6 months, no improvement in eGFR; as expected based on trials Wonder about market share of BEL vs voclo vs ANI - anyone seen pubs on this? #ACR25 @RheumNow Abstr#0661 https://t.co/l7i7IWhLSe

• https://x.com/EBRheum/status/1982478074810662970/photo/1

SELECT-GCA (upadacitinib in GCA for 52w) we hoped it might have ongoing effect post-cessation Do we need to continue upa? Extension data (second year) flare survival curves are clear: continuing upa far outperforms placebo It seems >2y toci/upa for GCA #ACR25 ABST0776 @RheumNow https://t.co/uJA3uQyWxb

• https://x.com/drdavidliew/status/1982476822744121513/photo/1

#0776 In the 2-yr SELECT-GCA trial, continued upadacitinib 15mg maintained remission in 69% vs 29% who switched to PBO, cutting flare risk by 90% and reducing steroid exposure by ~1g. No new safety signals in older adults (mean 71yrs). @RheumNow #ACR25 https://t.co/KC9sm3ic3q

• https://x.com/DrMiniDey/status/1982476564739620938/photo/1

Singla et al. In secukinumab phase 3 trials, fungal (inc candida) infections uncommon. 5.51 for sec vs 3.39 for PBO per 100PY. @RheumNow #ACR25 Abstr#585 https://t.co/g78zUsxD5a

• https://x.com/RichardPAConway/status/1982476060890649026/photo/1

Schmidt et al. 2 year results of SELECT-GCA, upadacitinib in GCA. Remission 69% if upa continued vs 29% if stopped. 90% lower risk of flare, 1G less steroid @RheumNow #ACR25 Abstr#0776 #ACRBest https://t.co/MgRo7kIgIw

• https://x.com/RichardPAConway/status/1982475306330935638/photo/1